Genetic Variation In The Estrogen Receptor-Alpha Gene (Esr1), Estrogen Exposure, And Risk Of Endometrial Cancer.
sandra l deming,wanqing wen,qiuyin cai,wanghong xu,nobuhiko kataoka,yongbing xiang,jiarong cheng,jirong long,wei zheng,xiaoou shu
IF: 11.2
2006-01-01
Cancer Research
Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006
5404 Previous studies have demonstrated that genetic polymorphisms in the estrogen receptor-alpha ESR1 gene are associated with altered risk of breast cancer. Given that ESR1 is an important mediator of hormonal responses in the endometrium, and that estrogen exposure is the prevailing risk factor for endometrial cancer, we hypothesized that genetic variations in the ESR1 gene may modulate the effects of estrogen exposure and thus alter endometrial cancer risk. We tested this hypothesis using data from a large population-based case-control study of endometrial cancer conducted in Shanghai, China, from 1997-2003. Included in this analysis were 1039 cases and 1026 age-matched community controls who had completed an in-person interview and donated a blood or exfoliated buccal cell sample to the study. Genotyping of ESR1 polymorphisms XbaI (rs9340799), and PvuII (rs2234693) in intron 1, and C →G Pro in codon 325 (rs1801132) were performed using the TaqMan method. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate associations between genetic variations of the ESR1 gene and endometrial cancer risk. In addition, ESR1 gene polymorphisms were evaluated for their role in modifying endogenous and exogenous estrogen exposures. Overall, no apparent association between endometrial cancer and the XbaI, PvuII, or Pro325 polymorphism was found. Similarly, haplotype analyses also did not reveal any associations that were statistically significant. Furthermore, we did not find that variants at these sites modify the risk of endometrial cancer associated with various estrogen exposures as measured by menopausal status, waist-to-hip ratio, body mass index, age at menarche and menopause, years of menstruation, history of physical activity, oral contraceptive use, and soy protein intake. Taken together, these data, from one of the largest population-based case-control studies of endometrial cancer, do not suggest a major role of the XbaI , PvuII , and 325Pro polymorphisms in the ESR1 gene in the risk of endometrial cancer.